AMR Action Fund CEO Henry Skinner was quoted by Bloomberg in a piece about Destiny Pharma and its struggles to raise capital for late-stage clinical trials of its antimicrobial asset.
When a company goes bankrupt or into administration, the worst-case scenario for an asset-in-development is that it “goes into the trash bin of history,” says Henry Skinner, CEO of the AMR Action Fund, a venture capital fund that invests in antimicrobial therapeutics. Another option is that it “gets sold for pennies — if there’s a buyer for it.”
Read the full article here.
